latest update:
[TrialBase DB]

trial summary · NCT07698535

Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial

Dynamic Assessments of Molecular Response to Guide Early 177Lu-PSMA-617 Treatment Discontinuation: The DYNAMO Study

Trial record from the TrialBase DB dataset, status RECRUITING, condition Metastatic Castration-Resistant Prostate Adenocarcinoma, sponsored by University of Washington. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07698535phase PHASE2enrollment 64start 2026-11-15

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This clinical trial studies whether measuring circulating tumor deoxyribonucleic acid (ctDNA) tumor fraction (TF) can be used to help guide the early stopping (discontinuation) of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) in patients with castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Many types of tumors tend to lose cells or release different types of cellular products including their deoxyribonucleic acid, which is referred to as ctDNA, into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for the disease to grow, spread, or get worse or come back after a period of improvement. ctDNA TF is a type of ctDNA measurement. Research has shown ctDNA TF may be a promising way to predict which patients will respond to 177Lu-PSMA-617 treatment. Measuring ctDNA TF may help doctors identify which patients may benefit from changing treatments sooner, which may be an effective way to guide early 177Lu-PSMA-617 treatment discontinuation in patients with metastatic castration-resistant prostate cancer.

Source record: https://clinicaltrials.gov/study/NCT07698535

Facts

registry idNCT07698535
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionMetastatic Castration-Resistant Prostate Adenocarcinoma
sponsorUniversity of Washington
sponsor classOTHER
enrollment64
start date2026-11-15
primary completion2029-07-05
completion2029-07-05
results postednot reported

Conditions

  • Metastatic Castration-Resistant Prostate Adenocarcinoma
  • Stage IVB Prostate Cancer AJCC v8

Interventions

  • Lutetium Lu 177 Vipivotide Tetraxetan
  • Cell-free Circulating Tumor DNA Assay
  • Computed Tomography
  • Docetaxel
  • PSMA PET Scan
  • Single Photon Tomography and Computed Tomography Scan
  • Biospecimen Collection

Countries

  • United States

Intervention types: DRUG, PROCEDURE

Work with this record